Eosinophilic granulomatosis with polyangiitis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:183M30.1
Who is this for?
Show terms as
2FDA treatments10Active trials43Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic small- and medium-vessel vasculitis characterized by asthma, peripheral and tissue eosinophilia, and necrotizing granulomatous inflammation. It belongs to the group of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, though only about 30-40% of patients are ANCA-positive (typically perinuclear ANCA targeting myeloperoxidase). EGPA affects multiple organ systems and typically progresses through three phases, though not all patients follow this sequence. The prodromal phase features allergic disease including asthma and allergic rhinitis or nasal polyposis. The eosinophilic phase involves marked peripheral blood eosinophilia and eosinophilic tissue infiltration, particularly affecting the lungs and gastrointestinal tract. The vasculitic phase involves systemic small-vessel vasculitis that can affect the heart, peripheral nerves, skin, kidneys, and gastrointestinal tract. Cardiac involvement (myocarditis, cardiomyopathy, pericarditis) is the leading cause of mortality. Peripheral neuropathy, particularly mononeuritis multiplex, is one of the most common manifestations. Skin lesions including purpura and nodules are frequently observed. Treatment depends on disease severity. Glucocorticoids are the cornerstone of therapy and are effective in many patients. For severe or refractory disease, immunosuppressive agents such as cyclophosphamide or azathioprine are used. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has been approved specifically for EGPA and has shown efficacy in reducing relapses and allowing glucocorticoid tapering. Rituximab is also used in refractory cases. With appropriate treatment, many patients achieve remission, though relapses are common and long-term management is often required.

Also known as:

Clinical phenotype terms— hover any for plain English:

Central nervous system degenerationHP:0007009Increased inflammatory responseHP:0012649Abnormal pericardium morphologyHP:0001697
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Oct 2025Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

Azienda Ospedaliero Universitaria di Cagliari — PHASE4

TrialENROLLING BY INVITATION
Apr 2025A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

AstraZeneca — PHASE3

TrialRECRUITING
Sep 2024

Fasenra: FDA approved

treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)

FDAcompleted
May 2024Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Imperial College London — PHASE2

TrialENROLLING BY INVITATION
Feb 2024eGPA and Local Inflammation Within the Ear, Nose and Throat Area

University Medical Center Groningen

TrialRECRUITING
Dec 2023Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NS Pharma, Inc. — PHASE2

TrialRECRUITING
Nov 2023A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE2, PHASE3

TrialRECRUITING
Jul 2022Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

GlaxoSmithKline — PHASE3

TrialACTIVE NOT RECRUITING
May 2022Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)

Assistance Publique - Hôpitaux de Paris — PHASE3

TrialACTIVE NOT RECRUITING
Jun 2019

NUCALA: FDA approved

NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Fasenra

benralizumab· AstraZeneca Pharmaceuticals LPOrphan Drug

treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)

NUCALA

mepolizumab· GlaxoSmithKline LLCOrphan Drug

NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Clinical Trials

10 recruitingView all trials with filters →
Phase 33 trials
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
Phase 3
Active
PI: Loic GUILLEVIN, MD, PhD (Assistance Publique - Hôpitaux de Paris) · Sites: Paris · Age: 1899 yrs
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Phase 3
Active
PI: GSK Clinical Trials (GlaxoSmithKline) · Sites: Denver, Colorado; Gainesville, Florida +74 more · Age: 1899 yrs
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Phase 3
Actively Recruiting
· Sites: Aurora, Colorado; Cincinnati, Ohio +11 more · Age: 617 yrs
Phase 41 trial
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Phase 4
Enrolling by Invitation
PI: STEFANO DEL GIACCO, MD (AZIENDA OSPEDALIERA UNIVERSITARIA CAGLIARI) · Sites: Cagliari, Cagliari · Age: 1899 yrs
Phase 22 trials
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
Phase 2
Enrolling by Invitation
PI: Salman Siddiqui, MBBS (Imperial College London) · Sites: Aberdeen; Birmingham +11 more · Age: 1875 yrs
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Phase 2
Actively Recruiting
· Sites: Denver, Colorado; Rochester, Minnesota +32 more · Age: 1899 yrs
Other3 trials
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Actively Recruiting
PI: Peter A. Merkel, MD, MPH (University of Pennsylvania) · Sites: San Diego, California; Denver, Colorado +11 more
eGPA and Local Inflammation Within the Ear, Nose and Throat Area
Actively Recruiting
· Sites: Groningen · Age: 1899 yrs
One-Time DNA Study for Vasculitis
Actively Recruiting
PI: Peter Merkel, MD, MPH (University of Pennsylvania) · Sites: Los Angeles, California; San Francisco, California +12 more · Age: 799 yrs

Specialists

Showing 25 of 43View all specialists →
AV
Augusto Vaglio
Specialist
9 Eosinophilic granulomatosis with polyangiitis publications
GE
Giacomo Emmi
Specialist
10 Eosinophilic granulomatosis with polyangiitis publications
AB
Alvise Berti
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
AB
Alessandra Bettiol
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
FB
Federica Bello
Specialist
6 Eosinophilic granulomatosis with polyangiitis publications
BH
Bernhard Hellmich
Specialist
6 Eosinophilic granulomatosis with polyangiitis publications
VC
Vincent Cottin
Specialist
6 Eosinophilic granulomatosis with polyangiitis publications
BT
Benjamin Terrier
Specialist
7 Eosinophilic granulomatosis with polyangiitis publications
MF
Marco Folci
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
MU
Maria Letizia Urban
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
CD
Cécile-Audrey Durel
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
MS
Maxime Samson
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
MG
Matthieu Groh
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
TN
Thomas Neumann
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
FM
Frank Moosig
Specialist
5 Eosinophilic granulomatosis with polyangiitis publications
PM
Peter A Merkel, MD, MPH
Tampa, Florida
Specialist

Rare Disease Specialist

PI on 7 active trials
CM
Christian Pagnoux, MD
Specialist
PI on 1 active trial
MM
Michael Wechsler, MD
DENVER, CO
Specialist
PI on 4 active trials
LP
Loic Guillevin, MD, PhD
Specialist
PI on 2 active trials
LP
Loic GUILLEVIN, MD, PhD
Specialist
PI on 1 active trial
RM
Robert Micheletti, MD
PHILADELPHIA, PA
Specialist
PI on 2 active trials
AF
Anoop J Chauhan, PhD FRCP
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Fasenra(benralizumab)AstraZeneca Pharmaceuticals LP

Travel Grants

No travel grants are currently matched to Eosinophilic granulomatosis with polyangiitis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Eosinophilic granulomatosis with polyangiitisForum →

No community posts yet. Be the first to share your experience with Eosinophilic granulomatosis with polyangiitis.

Start the conversation →

Latest news about Eosinophilic granulomatosis with polyangiitis

No recent news articles for Eosinophilic granulomatosis with polyangiitis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Eosinophilic granulomatosis with polyangiitis

What is Eosinophilic granulomatosis with polyangiitis?

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic small- and medium-vessel vasculitis characterized by asthma, peripheral and tissue eosinophilia, and necrotizing granulomatous inflammation. It belongs to the group of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, though only about 30-40% of patients are ANCA-positive (typically perinuclear ANCA targeting myeloperoxidase). EGPA affects multiple organ systems and typically progresses through three phases, though not all patients follow this sequence. The prod

How is Eosinophilic granulomatosis with polyangiitis inherited?

Eosinophilic granulomatosis with polyangiitis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Eosinophilic granulomatosis with polyangiitis typically begin?

Typical onset of Eosinophilic granulomatosis with polyangiitis is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Eosinophilic granulomatosis with polyangiitis?

Yes — 10 recruiting clinical trials are currently listed for Eosinophilic granulomatosis with polyangiitis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Eosinophilic granulomatosis with polyangiitis?

25 specialists and care centers treating Eosinophilic granulomatosis with polyangiitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Eosinophilic granulomatosis with polyangiitis?

1 patient support program are currently tracked on UniteRare for Eosinophilic granulomatosis with polyangiitis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.